In phase I clinical trials conducted on patients with different HER2-expressed breast cancer of all stages and IHC of 1+ to 3+, it was demonstrated that the vaccine has no significant effect on the DFS rate in patients with high HER2-expressing receptors on their breast tissue [69]. The gene discussed is ERBB2; the disease is breast carcinoma.